Reference health
Further Preclinical Characterization of Molnupiravir Against SARS-CoV-2: Antiviral Activity Determinants and Viral Genome Alteration Patterns
29/29 checkable references clean · checked 2026-07-24
Every reference with a DOI or an arXiv id in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
14 with no DOI or arXiv id: not checked. A reference deposited without a DOI is checked only when it names an arXiv id, under that id’s DataCite DOI. The rest are never matched by title or guessed at; they stay outside the checked set, and this line says so.
The 29 checked references that resolve
resolves10.1177/095632020401500102
Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N<sup>4</sup>-Hydroxycytidine
resolves10.1016/S0140-6736(22)02597-1
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
resolves10.1056/EVIDoa2100043
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
resolves10.1016/j.antiviral.2021.105212
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
resolves10.1038/s41564-020-00835-2
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
resolves10.1038/s41467-022-34839-9
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
resolves10.1128/AAC.02395-16
Characterization of β-
<scp>d</scp>
-
<i>N</i>
<sup>4</sup>
-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus
resolves10.3390/microorganisms10071475
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
resolves10.1056/NEJMoa2116044
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
resolves10.1016/j.antiviral.2022.105430
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
resolves10.1016/j.antiviral.2022.105492
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
resolves10.1073/pnas.2014441117
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
resolves10.1093/jac/dkab318
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
resolves10.1002/slct.201703052
Selective Inhibition of
<i>Enterovirus A</i>
Species Members’ Reproduction by Furano[2, 3‐
<i>d</i>
]pyrimidine Nucleosides Revealed by Antiviral Activity Profiling against (+)ssRNA Viruses
resolves10.1016/S2213-2600(14)70041-4
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
resolves10.1002/rmv.2133
Remdesivir: A beacon of hope from Ebola virus disease to <scp>COVID</scp>‐19
resolves10.1016/j.antiviral.2019.104597
The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection
resolves10.1016/j.xcrm.2020.100059
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia
resolves10.1038/s41467-021-22580-8
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
resolves10.15252/emmm.202013105
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
resolves10.1128/AAC.47.1.244-254.2003
Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture
resolves10.1358/dnp.2009.22.2.1343228
The value of drug repositioning in the current pharmaceutical market
resolves10.1016/j.antiviral.2021.105137
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
resolves10.1038/s41586-021-03312-w
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
resolves10.1002/em.22471
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir
The 14 references with no DOI or arXiv id, listed, not checked
no DOI — not checkedref1
no DOI — not checked2022a. The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
no DOI — not checkedA robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
no DOI — not checkedPre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
no DOI — not checkedSARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
no DOI — not checkedref23
no DOI — not checkedref24
no DOI — not checkedInhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle
no DOI — not checkedA molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
no DOI — not checkedAn orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
no DOI — not checkedCharacterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
no DOI — not checked2018. ?-D -N 4 -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
no DOI — not checkedOrally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
no DOI — not checkedIs Also Mutagenic To Mammalian Cells
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. If Crossref’s record marks the work itself
retracted, withdrawn, or removed, the badge says so instead of showing clean. It says nothing
about the quality, findings, or importance of the work itself, and nothing about references
with neither a DOI nor an arXiv id.
checked 2026-07-24 — re-checked at most once a day, when someone opens this page, so the date shown is the last check; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge shows the date of its last check, which runs at most once a day, when someone opens this page.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4735572"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4735572/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4735572)